Sorrento Therape (SRNE)

Sorrento Therape (SRNE) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $441,024; returns 1 day -66.7%.

Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Their primary areas of focus include oncology, pain management, autoimmune disorders, and infectious diseases. Sorrento leverages its proprietary G-MAB™ human antibody library and other innovative platforms to develop novel drugs and biologics.

Groups SRNE belongs to

• Biotechnology
• Clinical Stage Biopharma
• Biopharmaceutical
• Oncology
• Pain Management
• Antibody Therapeutics
• Autoimmune Diseases
• Infectious Diseases
• Monoclonal Antibodies
• Unmet Medical Needs
• Healthcare

SRNE financial model: income statement, cash flow and balance sheet